There are five key reasons why OSE may be considered an attractive investment.

First, OSE has a diverse pipeline of assets, backed by science at the forefront of immunotherapy research, offering multiple shots at goal. 

This covers the promising therapeutic markets of immuno-oncology and immuno-inflammation. Lead oncology candidate Tedopi is an off-the-shelf, neoepitope-based cancer vaccine. It is in a registrational Phase III trial for non-small-cell lung cancer and holds promise in capturing a share of this $60bn therapeutic market. Lead inflammation candidate lusvertikimab recently showed highly encouraging results in Phase II for ulcerative colitis, providing a robust foundation for further clinical development efforts. Overall, OSE has more than eight in-house and partnered programmes, five of which are in the clinical stage, offsetting the company’s binary event risk exposure. 

Second, OSE has a track record of partnering with pharma players.

As success in the sector often stems from partnering, OSE preferentially targets industry leaders. It is currently eligible for over €2.1bn in potential milestones. OSE’s partners include AbbVie, Boehringer Ingelheim and Veloxis. These partnerships provide crucial non-dilutive funding, while also validating OSE’s R&D capabilities. 

Third, OSE is a platform company with four cutting-edge preclinical platforms offering broad potential to create a diverse pipeline of first-in-class therapies with a host of applications.

The Pro-resolute mab platform advances inflammation resolution, optimising the potential of targeting neutrophils and macrophages. The Myeloid Checkpoint platform restores tissue integrity by modulating immune cells. BiCKI is a bifunctional fusion protein platform combining anti-PD1 with new immunotherapy targets. The mRNA Therapeutic platform provides local delivery of immunotherapies encoded by RNA into inflammatory sites.

Fourth, the company is led by a highly experienced executive leadership team with a proven track record in drug development and business execution.

CEO Nicolas Poirier PhD has been a member of the team since 2016 and was appointed CEO in 2022. Nicolas and his team have obtained more than €45m in French and European public funding to co-finance OSE’s programmes. Chief development officer Sonya Montgomery brings over 20 years of pharma and biotech experience, and chief clinical and medical research officer Silvia Comis MD has over 30 years of leadership experience.

Finally, OSE has a robust financial position and an attractive outlook for growth.

The company has a safe cash runway to Q127. Looking ahead, it remains committed to responsible financing to support long-term growth. Positive data, multiple partnerships and an expanding pipeline, all backed by a strong executive leadership team, underpin OSE’s outlook for value appreciation.

In conclusion, OSE presents a compelling investment case. It is well-equipped to address unmet patient needs of today and tomorrow and well-positioned for attractive market performance.

Published 29 August 2025